Product Images Vitrakvi
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 24 images provide visual information about the product associated with Vitrakvi NDC 71777-392 by Loxo Oncology, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
image of 100 mg carton principal panel - 60 capsules - carton caps 100
VITRAKVI® is a medication available in capsule form with a strength of 100mg. It contains Larotrectinib, an effective ingredient equivalent to 123mg Larotrectinib sulfate. This medication is meant for oral administration and comes in a bottle containing 60 capsules.*
image of 25 mg carton principal panel - 60 capsules - carton caps 25
VITRAKVI® is an oral medication available in the form of capsules containing 25 mg of larotrectinib sulfate. It is a prescription medication utilized for the treatment of certain types of cancer. The package contains 60 capsules for oral use.*
image of 20 mg/mL carton principal panel - 100 mL oral solution - carton sol
VITRAKVI® is an oral solution medication with 20mg/mL Larotrectinib for oral use, packaged in a 100mL bottle. Each bottle contains Larotrectinib equivalent to 24.6mg/mL tarotrectini sulfate.*
image of the chemical structure of VITRAKVI - chem struct
image of supplies needed to take or give a dose of VITRAKVI oral solution - fig a
This text describes a figure labeled as "Figure A" that includes a bottle, an oral syringe, a 5mL oral syringe, and a bottle adaptor.*
image of how to open the bottle - fig b
image of how to insert the adaptor into the bottle - fig c
image of the oral syringe and a close up of the markings in mL - fig d
image of of how to insert the oral syringe into the bottle - fig e
image of how to draw VITRAKVI into the oral syringe for proper dose - fig f
image of how to expell air bubbles in the oral syringe - fig g
image of how to remove the oral syringe from the bottle - fig h
image of how to properly press the plunger to deliver the dose - fig i
image of recapping the bottle - fig j
image of removing the plunger from the barrel of the oral syringe - fig k
image of rinsing the oral syringe (plunger and barrel) - fig l
image of re-insertion of plunger into oral syringe barrel - fig m
image of cleaning oral syringe using warm water - fig n
image of rinsing the plunger and barrel of the oral syringe a 2nd time - fig o
image of shaking excess water from the barrel and plunger - fig p
image of where to write the date of when the bottle was opened - fig q
image of 100 mg label principal panel - 60 capsules - label caps 100
NDC 71777-391-01 is a medication manufactured by Lovo Oncology Inc. The medication is in capsule form and is called Larotrectinib. Each capsule contains 100mg of Larotrectinib (equivalent to 13mg of Larotrectinib sulfate). The usual dosage information can be found in the prescribing information. The medication should be stored between 20°C to 25°C (68°F to 77°F) and can be kept between 15°C to 30°C (9°F to 86°F) with permission. The medication should be kept away from children.*
image of 25 mg label principal panel - 60 capsules - label caps 25
This is a drug information label for VITRAKVI® (Larotrectinib) capsules with the NDC code 71777-390-01. The label mentions the dosage and that it should only be taken with a prescription. The label advises keeping the capsules out of reach of children and storing them at room temperature. The manufacturer of the drug is also provided. The remaining text seems to be an error or not related to the drug information.*
image of 20 mg/mL label principal panel - 100 mL oral solution - label sol
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.